Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia at the Annual Meeting of the American Society of Clinical Oncology Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia ... (more)
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Ambit-Announces-Presentation-of-Results-from-Phase/ArticleNewsFeed/Article/detail/814745?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Ambit-Announces-Presentation-of-Results-from-Phase/ArticleNewsFeed/Article/detail/814745?ref=25
No comments:
Post a Comment